Concord Drugs Ltd vs Unichem Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Concord Drugs Ltd is ₹ 77.31 as of 12 Jun 15:30 . The P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 91.4 on March 2025 . This represents a CAGR of 54.84% over 4 yearsThe P/E Ratio of Unichem Laboratories Ltd changed from 63.4 on March 2021 to 35.5 on March 2025 . This represents a CAGR of -10.95% over 5 years The Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 31.08 crore on March 2025 . This represents a CAGR of 5.22% over 4 yearsThe Market Cap of Unichem Laboratories Ltd changed from ₹ 2177 crore on March 2021 to ₹ 4877 crore on March 2025 . This represents a CAGR of 17.50% over 5 years The revenue of Concord Drugs Ltd for the Mar '26 is ₹ 37.9 crore as compare to the Dec '25 revenue of ₹ 16.99 crore. This represent the growth of 123.07% The revenue of Unichem Laboratories Ltd for the Mar '26 is ₹ 598.59 crore as compare to the Dec '25 revenue of ₹ 808.49 crore. This represent the decline of -25.96% The ebitda of Concord Drugs Ltd for the Mar '26 is ₹ 1.5 crore as compare to the Dec '25 ebitda of ₹ 0.94 crore. This represent the growth of 59.57% The ebitda of Unichem Laboratories Ltd for the Mar '26 is ₹ 58.79 crore as compare to the Dec '25 ebitda of ₹ 332.1 crore. This represent the decline of -82.3% The net profit of Concord Drugs Ltd changed from ₹ 0.03 crore to ₹ 0.53 crore over 8 quarters. This represents a CAGR of 320.32% The net profit of Unichem Laboratories Ltd changed from ₹ 2.07 crore to ₹ 10.91 crore over 8 quarters. This represents a CAGR of 129.58% The Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Unichem Laboratories Ltd changed from 52.07 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

About Unichem Laboratories Ltd

Unichem Laboratories Limited manufactures active pharmaceutical ingredients.
The company operates through four divisions, namely Unichem Pharma Division, Unichem Specialities Division, Unisearch Division and Neu-Foreva Division.
The company is headquartered in Mumbai with five manufacturing facilities located at Roha in Maharashtra, Goa, Ghaziabad in Uttar Pradesh, Pithampur in Madhya Pradesh and Baddi in Himachal Pradesh. The company's facilities enjoy credible certifications, the Goa plant was approved by UK MHRA, MCC (South Africa), WHO (Geneva) and TGA (Australia).
The Baddi plant was approved by UK MHRA and MCC (South Africa).
The company received ISO 9001:2000 for all their plants and corporate office.

FAQs for the comparison of Concord Drugs Ltd and Unichem Laboratories Ltd

Which company has a larger market capitalization, Concord Drugs Ltd or Unichem Laboratories Ltd?

Market cap of Concord Drugs Ltd is 101 Cr while Market cap of Unichem Laboratories Ltd is 3,140 Cr

What are the key factors driving the stock performance of Concord Drugs Ltd and Unichem Laboratories Ltd?

The stock performance of Concord Drugs Ltd and Unichem Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Drugs Ltd and Unichem Laboratories Ltd?

As of June 14, 2026, the Concord Drugs Ltd stock price is INR ₹77.31. On the other hand, Unichem Laboratories Ltd stock price is INR ₹446.1.

How do dividend payouts of Concord Drugs Ltd and Unichem Laboratories Ltd compare?

To compare the dividend payouts of Concord Drugs Ltd and Unichem Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.